and development of
new antibiotics and
The Netherlands Antibiotic Development Platform
The Netherlands Antibiotic Development Platform (NADP) facilitates the collaboration between public and private organisations, to enhance the development of new antibiotics and alternative therapies for infectious diseases in humans and animals.
NADP will identify relevant research groups, institutes and companies involved in chemical, biological, and/or biomedical antibiotic research to forge collaborations through targeted connections and will organise regular meetings with interested parties. At a later stage, the NADP will provide Drug Discovery Management support/vouchers and Intellectual Property and Technology Transfer Office support.
NADP supports R&D collaborations. To give further insights in companies active in this area, we have initiated a “Company in the spotlight” issue. In this first edition, we speak to Dr. Andreas Bastian, the CEO of AGILeBiotics B.V. This antimicrobial developing company was founded earlier this year and is a perfect candidate to kick-off this topic!Read more
The five awarded projects will investigate the beneficial effects of carbohydrates on microorganisms in the gastro-intestinal tract. The results are expected to aid in the reduction of antibiotics use in humans and farm animals. A total of 2.5 million Euros is invested in these projects, including contributions of TKI Agri&Food, Avebe, FrieslandCampina and NutritionSciences.Read more
A list of funding opportunities, with topics around antimicrobial resistance, development of new antibiotics and alternative therapies.